Exploiting research at University of Pittsburgh and UPMC, Novasenta has been established with $20m in seed financing.
Novasenta, a US-based developer of cancer treatments, has been formed with $20m in seed capital to advance research at University of Pittsburgh (Pitt) and its health system affiliate, UPMC.
UPMC Enterprises, the innovation arm of UPMC, contributed to the seed round. No other investors were identified.
Founded in 2018, Novasenta is working on immunotherapies targeting the tumour microenvironment. It is based on work by co-founders Dr Robert Ferris, Dario Vignali and Greg Delgoffe, faculty members at the UPMC…
